Dr. Marshall on the Results of the DESTINY-Gastric02 Trial in Gastric/GEJ Cancer


In Partnership With:

John L. Marshall, MD, discusses the results of the phase 2 DESTINY-Gastric02 trial in HER2-positive gastric and gastroesophageal junction cancers.

John L. Marshall, MD, chief, Division of Hematology/Oncology at Georgetown University Hospital, associate director, Clinical Research, Georgetown Lombardi Comprehensive Cancer Center, discusses the results of the phase 2 DESTINY-Gastric02 trial (NCT04014075) in HER2-positive gastric and gastroesophageal junction (GEJ) cancers.

The DESTINY-Gastric02 trial is an extension of the phase 2 DESTINY-Gastric01 trial (NCT03329690) in the Western population of patients with metastatic HER2-positive gastric/GEJ cancer, Marshall explains. DESTINY-Gastric02 enrolled patients with metastatic gastric/GEJ cancer who had previously received HER2-targeted treatments including frontline trastuzumab (Herceptin), which is where trastuzumab is currently considered standard, Marshall explains. As such, patients received fam-trastuzumab deruxtecan-nxki (Enhertu) as second- or later-line treatment, Marshall adds.

The results of the trial demonstrated a response rate of 38%, which comprised 3 complete responses and 27 partial responses. Many attempts have been made to targeting HER2 after frontline therapy without success, Marshall says. Overall, the data from DESTINY-Gastric02 represent a breakthrough in the treatment of patients with HER2-positive gastric/GEJ cancer and further emphasize a need to enforce efficient molecular profiling in this patient population, Marshall concludes.

Related Videos
Marc J. Braunstein, MD, PhD
Paul D. Nathan, MBBS, PhD, FRCP
Guru P. Sonpavde, MD
Arpita Desai, MD
Qian (Janie) Qin, MD
Melissa L. Johnson, MD
Adrienne Phillips, MD, MPH
Jeffrey S. Weber, MD, PhD
Manojkumar Bupathi, MD, MS
Mylin A. Torres, MD